A Study of Mirikizumab in Participants With Plaque Psoriasis

Completed · Phase 1

Conditions studied: Psoriasis

In brief

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

Key facts

Study ID: NCT03718884
Run by: Eli Lilly and Company
People needed: 29
Starts: 2018-10-23
Expected to finish: 2019-10-28
Last updated by the study team: 2024-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Males and females with chronic plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy
Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at screening and first admission to the clinical site

You may not qualify if…

Pregnant or nursing (lactating)
History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
Have major surgery within 8 weeks prior to first admission to the clinical site or during the study
Have a history of lymphoma, leukemia, or any malignancy
Require treatment with the cocktail drugs within 14 days prior to the first administration of the drug cocktail through the end of Week 12 assessments
Have participated in any other study with mirikizumab

Where it is running

Anaheim Clinical Trials, LLC — Anaheim, California, United States
Avail Clinical Research LLC — DeLand, Florida, United States
High Point Clinical Trials Center — High Point, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.